Rubicon Research Acquires 85% Stake in Arinna for Rs 176 Cr, Enters CNS Market
New Delhi: Rubicon Research Limited has acquired an 85% equity stake in Arinna Lifesciences Limited for approximately Rs 175.92 crore, valuing the company at Rs 200 crore enterprise value, as part of its strategy to expand into the Indian CNS formulations market and strengthen its domestic presence.
The acquisition marks Rubicon’s entry into India’s central nervous system (CNS) therapeutic segment through Arinna, which has a portfolio of over 60 brands focused on chronic therapies and a network of more than 4,000 prescribers supported by an established distribution system across the country.
The deal has been executed on a cash and debt-free basis, with Rubicon purchasing shares at ₹158.53 per share. The final consideration may be subject to adjustments at closing. For the nine months ending December 31, 2025, Arinna reported provisional revenue of ₹56.7 crore and EBITDA of ₹9.5 crore.
The acquisition is aligned with Rubicon’s broader strategy of leveraging its intellectual property and chronic product portfolio to drive growth in key therapeutic segments. The company aims to utilise Arinna’s strong domestic distribution network to expand access to its differentiated offerings, including specialty products and drug-device combinations.
Commenting on the development, CEO Parag Sancheti highlighted that strategic acquisitions have been central to Rubicon’s growth, enabling it to expand into new segments such as US branded specialty products and nasal drug delivery platforms in recent years. He noted that Arinna provides a strong platform for scaling the company’s presence in the Indian market.
Post-acquisition, Arinna’s founder Vivek Seth will retain a 15% stake and continue to serve as Managing Director, ensuring continuity in leadership and operations. The transaction is expected to be completed within 30 days, subject to customary closing conditions.
Rubicon Research, established in 1999, operates as an integrated pharmaceutical company with capabilities spanning research and development, manufacturing, and commercialization of differentiated products. The company has a portfolio of over 80 pharmaceutical products across multiple therapeutic areas and operates globally inspected manufacturing facilities approved by regulators such as the USFDA, UK MHRA, and Australia’s TGA.
